Death · people with Down syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behavioural problems: overall · people with Down syndrome
1 finding from 1 review
Adverse events · people with Down syndrome
Comparison 1: donepezil may leads to lower adverse events compared with placebo (low certainty).
1 finding from 1 review
Carer stress · people with Down syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Institutional/home care · people with Down syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · people with Down syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome measure: cognitive abilities at the end of · people with Down syndrome
1 finding from 1 review
Behavioural problems: overall · people with Down syndrome
1 finding from 1 review
Adverse events · people with Down syndrome
Comparison 2: memantine showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Repetition of SH at last · adults who engage in SH
Newer generation antidepressants showed no clear difference in repetition of SH at last compared with placebo (low certainty).
1 finding from 1 review
Repetition of SH at 6 months' · adults who engage in SH
It is very uncertain whether antipsychotics changes repetition of SH at six months (flupenthixol vs. placebo) compared with placebo or another comparator drug/dose (very low certainty).
1 finding from 1 review
Repetition of SH at six months (low dose fluphenazine vs. ultra low dose fluphenazine) · adults who engage in SH
It is very uncertain whether antipsychotics changes repetition of SH at six months (low dose fluphenazine vs. ultra low… compared with placebo or another comparator drug/dose (very low certainty).
1 finding from 1 review
Repetition of SH at 12 months · adults who engage in SH
Mood stabilisers showed no clear difference in repetition of SH at 12 months compared with placebo (low certainty).
1 finding from 1 review
Repetition of SH during 12 week treatment phase · adults who engage in SH
Natural products showed no clear difference in repetition of SH during 12 week treatment phase compared with placebo (low certainty).
1 finding from 1 review
Treatment efficacy CAPS, CIDI · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…
Propranolol showed no clear difference in treatment efficacy CAPS, CIDI compared with placebo (low certainty).
1 finding from 1 review
Treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…
Hydrocortisone probably leads to lower treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I compared with placebo (moderate certainty).
1 finding from 1 review
Angiotensin receptor blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Intervention not reported
Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin receptor blocker (medium‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review